Porcine Extracellular Matrix Nerve Wrap in Neck Dissection for Head and Neck Cancer
NCT07268092 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2025-12-05
Summary
Perform a preliminary efficacy study using the porcine extracellular matrix nerve wrap (AxoGuard Nerve Protector™, AxoGen Inc., Alachua, FL) to wrap the spinal accessory nerve (SAN) during neck dissections for head and neck cancer as it relates to postoperative shoulder function, both subjectively and objectively.
Conditions
- Head and Neck Cancer
- Neck Dissection
- Postoperative Complications
Interventions
- DEVICE
-
Porcine Extracellular Matrix Nerve Wrap (AxoGuard Nerve Protector™)
The intervention involves the application of the AxoGuard Nerve Protector™, a nerve wrap derived from porcine extracellular matrix (ECM), to the spinal accessory nerve (SAN) during neck dissection surgery in head and neck cancer patients. The device is designed to protect and support the nerve by preserving the extracellular matrix and creating a favorable environment for nerve healing. This helps prevent inflammation and fibrosis around the nerve, potentially improving postoperative shoulder function. The nerve wrap is applied intraoperatively after dissection but before surgical closure. The study compares this intervention to standard neck dissection without nerve wrapping.
Sponsors & Collaborators
-
Henry Ford Health System
lead OTHER
Principal Investigators
-
Samantha Tam, MD · Henry Ford Health System
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-25
- Primary Completion
- 2026-08-12
- Completion
- 2026-08-12
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
NCT04470024 ·Status: RECRUITING ·Phase: PHASE1
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
NCT04323202 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
NCT00004070 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer
NCT02079324 ·Status: COMPLETED ·Phase: PHASE1
-
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07055841 ·Status: RECRUITING ·Phase: PHASE2
-
Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer
NCT06775756 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer
NCT01053546 ·Status: TERMINATED ·Phase: NA
-
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00281840 ·Status: COMPLETED ·Phase: PHASE2
-
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
NCT02918955 ·Status: COMPLETED ·Phase: PHASE3
-
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
NCT00089297 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT06980038 ·Status: RECRUITING ·Phase: PHASE2
-
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00736619 ·Status: COMPLETED ·Phase: PHASE1
-
A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
NCT00483821 ·Status: COMPLETED
-
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
NCT00646659 ·Status: TERMINATED ·Phase: PHASE2
-
Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer
NCT02554968 ·Status: COMPLETED
-
Treatment of Advanced Head and Neck Cancer
NCT00982696 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
NCT04938609 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
NCT02031250 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
NCT02126969 ·Status: COMPLETED ·Phase: PHASE2
-
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
NCT00158652 ·Status: COMPLETED ·Phase: PHASE3
-
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NCT04862455 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT04831450 ·Status: WITHDRAWN ·Phase: PHASE2
-
Neuropathic Pain in Head and Neck Cancer
NCT01846286 ·Status: UNKNOWN
-
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
NCT06308913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1